Stay updated with breaking news from Cassava Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.
/PRNewswire/ -- The prevalence of Alzheimer's disease has been rising over the past few years, which prompts the growing demand for treatment options. The...
/PRNewswire/ -- The "Alzheimer's Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis 2023-2028" report has been added to ResearchAndMarkets....
953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment Goal Is to Complete...
It isn't about running out of money, but it's still laden with risk.